Eli Lilly invests weight loss drug profits to build a "Research App Store" for scientists

Source: Global Market Report

To hedge against operational risks arising from expiring patents on its blockbuster weight loss drugs, this pharmaceutical giant is investing its ample cash into the development of multiple new drugs that have yet to be validated by the market through a new R&D model. This includes an integrated AI platform for life science researchers, akin to the Apple App Store.

This Indianapolis-based pharmaceutical company built its own data center last year, purchasing 1,016 next-generation Nvidia Blackwell high-end computing chips, and has been extensively investing in the artificial intelligence-driven drug R&D track.

Eli Lilly CEO Dave Ricks revealed in an interview with the British media that the company’s computational power investment is paired with a brand-new collaboration program: joining forces with about 100 small and medium-sized biotech firms, permitting these companies to leverage Lilly’s AI R&D models in exchange for sharing their respective experimental data.

He admitted that relying solely on AI to develop new drugs is still in its infancy, but this project is positioned as the “app store” for the biopharmaceutical research community, mirroring the model where the Apple App Store triggered an explosion in the software development industry.

“Many AI founders claim in talks that ‘we can develop new drugs with just computers alone,’ but I don’t think that’s realistic right now,” he said. “Yet, of course, we must continue to invest in these cutting-edge technologies.”

Weight loss products are the core driving force behind Eli Lilly’s revenue growth, with representative products including tirzepatide injection and the oral weight loss drug Zepbound. The company’s Q1 profit more than doubled year-on-year, with earnings per share surging to $8.26.

By the end of 2025, Eli Lilly’s cash and highly liquid assets reached $7.3 billion, a year-on-year increase of 121%. With abundant capital reserves, Eli Lilly is able to aggressively push a diversified portfolio to address industry challenges as multiple flagship weight loss drug patents begin to expire in the 2030s.

Several biotech companies have already joined Lilly’s AI joint R&D platform, including Charles River Laboratories, which officially announced its participation last week.

Ricks said: “This system adopts an open-source collaborative modeling architecture. The price for using the platform’s resources is that companies must share their own data, all of which will be anonymized. Our internal researchers will also use these models, allowing the algorithms to continuously iterate and improve.”

This year marks the 150th anniversary of the pharmaceutical company’s founding. Eli Lilly disclosed that it has signed approximately 20 third-party AI technology licensing agreements. According to UBS data, as of May, this number ranks first among global pharmaceutical companies.

In March this year, Eli Lilly also reached a $2 billion agreement with the AI drug discovery company Insilico Medicine. If a GLP-1 targeted drug jointly developed by both parties is successful and approved for the market, Eli Lilly will have exclusive sales rights for the drug.

Ricks added that this AI R&D center is not open to all organizations—a Russian AI lab, for example, will not be granted platform access.

Although the technical pathway for using AI in new drug development has yet to be fully validated, Eli Lilly’s continued investment highlights the pharmaceutical industry’s heightened vigilance toward technological crossovers and potential future competition from the tech sector.